Alzheimer's disease (AD) is characterised by the progressive loss of cognitive function, memory impairment, and behavioural changes. It remains one of the most challenging and prevalent neurodegenerative disorders, affecting millions of individuals worldwide.
One of the visible features in the brains of people with Alzheimer's disease is the formation of amyloid plaques – clumps of β-amyloid (Aβ) peptides, which are degraded products of amyloid precursor protein (APP). These Aβ-fragments accumulate in neurons early in the disease, even before cognitive decline is observed.
New research, however, suggests that there might even be earlier events happening in the AD brain before plaque formation and that the APP protein plays a role in these early stages. The mechanism behind this remained a mystery until now. In a new study published in Developmental Cell, researchers from the lab of Wim Annaert, at the VIB-KU Leuven Center for Brain & Disease Research, have identified a novel mechanism potentially connected to the early stages of AD. They demonstrated that a fragment of the amyloid precursor protein (APP), called APP-CTF, disrupts communication between cellular compartments crucial for calcium storage and waste disposal, which could be an early event preceding neuronal cell death.
These findings, with potential implications for the development of new AD treatments, suggest that preventing APP-CTF accumulation needs to be taken into account to develop more effective treatments.
Web design by Tribal Systems